Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hepatology. 2014 Feb 28;59(4):1577–1590. doi: 10.1002/hep.26898

Figure 5. Erlotinib reverses a gene expression signature associated with poor survival in human cirrhosis and HCC patients.

Figure 5

Male Wistar rats received PBS or DEN for 8, 12 or 18 weeks. DEN-injured rats received erlotinib (0.5 or 2 mg/kg) during weeks 13 – 18. GSEA analysis of the (A) 73-gene poor-prognosis signature and (B) 113- gene good-prognosis signature in DEN rats after treatment with erlotinib. (C) Heat maps are shown for several pro-fibrogenic genes.